These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25944411)

  • 1. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
    HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
    Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
    J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.
    Grey A; Bolland MJ; Wattie D; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2009 Feb; 94(2):538-44. PubMed ID: 19050050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
    Klaus J; Haenle MM; Schröter C; Adler G; von Boyen G; Reinshagen M; von Tirpitz C
    Am J Gastroenterol; 2011 Apr; 106(4):786-93. PubMed ID: 21386830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
    Bourke S; Bolland MJ; Grey A; Horne AM; Wattie DJ; Wong S; Gamble GD; Reid IR
    Osteoporos Int; 2013 Jan; 24(1):349-54. PubMed ID: 22893357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
    Huang J; Meixner L; Fernandez S; McCutchan JA
    AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.
    Pinzone MR; Moreno S; Cacopardo B; Nunnari G
    AIDS Rev; 2014; 16(4):213-22. PubMed ID: 25300622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
    Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
    Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
    Okazaki R; Hagino H; Ito M; Sone T; Nakamura T; Mizunuma H; Fukunaga M; Shiraki M; Nishizawa Y; Ohashi Y; Matsumoto T
    Osteoporos Int; 2012 Jun; 23(6):1737-45. PubMed ID: 21932114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.